Skip to main content
HairCited

Treatments for androgenetic alopecia and alopecia areata: current options and future prospects.

V M Meidan, E Touitou
Review Drugs 2001 48 次引用
PubMed DOI
<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'pmid\u003D11217871'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

研究类型
Review
研究人群
Androgenetic alopecia and alopecia areata patients
干预措施
Treatments for androgenetic alopecia and alopecia areata: current options and future prospects. Minoxidil, finasteride, spironolactone, steroids
对照组
None
主要结局
Hair loss treatment outcomes
效应方向
Positive
偏倚风险
Unclear

Abstract

Androgenetic alopecia and alopecia areata are common disorders of the hair follicle which may heavily influence self esteem and self image. Androgenetic alopecia is caused by the heightened sensitivity of scalp follicles to dihydro- testosterone whereas alopecia areata is induced by an autoimmune reaction. Current drug treatment approaches include the use of regrowth stimulators such as topical minoxidil and oral finasteride for androgenetic alopecia, as well as topical minoxidil, dithranol (anthralin), corticosteroids, contact sensitisers, and psoralen plus ultraviolet A irradiation (PUVA) therapy for alopecia areata. Combination regimens are also proposed. However, extreme cases of either type of alopecia do not generally respond well to these existing treatments. For this reason, new therapeutic strategies are directed towards both improving the targeting of existing agents, as well as the development of novel hypertrichotic modalities.

简要概述

New therapeutic strategies are directed towards both improving the targeting of existing agents, as well as the development of novel hypertrichotic modalities for androgenetic and alopecia areata.

Used In Evidence Reviews

Similar Papers